Posted by AGORACOM
at 12:08 PM on Monday, May 31st, 2021
When it comes to small-cap companies, tech-focused Datametrex AI is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.
In our newest interview with Datametrex, we sit down with CEO Marshall Gunter to discuss the company’s record-breaking Q1 2021, their explosive AI business, their incredibly successful foray into the COVID-19 market, and more.
Record Q1 Revenue of $19.04 Million up 2,253%
Record Adjusted EBITDA of $10.68 Million up 1,548%
Novamind COO Pierre Bou-Mansour discusses rapid expansion, staying consistent and Novamind’s ultimate goal.
“We want to set a new standard of mental healthcare, and be the network that patients prefer—to become a trusted partner for innovative mental healthcare.”
Focused on creating a safe space “to incorporate psychedelic medicine into recovery,” Dimitri M. is a living embodiment of the wounded healer. A former heroin addict whose life was changed by Ibogaine and a 12-step program. Since he’s gone on to form Psychedelics in Recovery and is holding up to 17 meetings a week over zoom. Access to psychedelic medicine in the right situation can be life-changing. Dr. Reid Robison calls psychedelics “therapy accelerators.” Learn more about our innovative approach to psychedelic medicine here.
A study that had been on hold for almost two years has been approved. MAPS will hold a phase 1 clinical trial of MDMA-assisted therapy for healthcare workers. Working in conjunction with the FDA, MAPS was able to win the appeal and help “improve the regulatory landscape for all future patients of psychedelic-assisted medicines.” The study “will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients.” This study will address a critical area of need for healthcare workers.
To say the partnership between Loop Insights and one of Canada’s largest telecommunications companies ($15.5 billion in annual revenue in 2020 and 16 million customer connections) was an understatement.
Posted by AGORACOM-JC
at 4:03 PM on Thursday, May 20th, 2021
The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.
If you believe in the massive paradigm shift towards plant based foods and more, be sure to watch and share this great interview with PlantX CEO Julia Frank.
Posted by AGORACOM
at 8:28 PM on Wednesday, May 19th, 2021
To understand the value proposition of TAAT, you first have to understand some recent massive trends in the Consumer Packaged Goods (CPG) space:
Non-alcoholic beer has grown into a $18bn USD market
The plant-based alternative meat market is projected to hit $74bn USD by 2027
What do they have in common? Providing consumers of the original products with almost the exact same experience (taste, smell, et cetera), without the negative parts of the original products.
Enter TAAT.
Tobacco is used by 1.3bn people worldwide, with a market that exceeds $930bn USD – many of whom wish to leave nicotine behind.
Under the administration of experienced leaders from the tobacco industry, TAAT™ Global Alternatives has developed a nicotine-free and tobacco-free smoking experience (known as TAAT™), which has already launched in the USA to tremendous feedback.
Now, the company has penned a major deal to launch its Beyond Tobacco™ cigarettes into the UK and Ireland, and recently leased two new Nevada facilities, increasing total space by more than 250%.
What does this mean for the firm’s distribution plans?
We sat down with TAAT CEO Setti Coscarella to find out…
Posted by AGORACOM
at 4:16 PM on Tuesday, May 18th, 2021
Arctic Star Exploration (ADD:TSXV / ASDZF:OTCQB ) is in the diamond finding business.
Arctic Star has spent years building up to the moment where it could say it made a discovery. Now it can. Four times over, and potentially a whole field of Kimberlites that may contain diamonds. And they have done this by merely looking where no one had considered previously.
The spring 2021 exploration program on the Diagras project, Lac de Gras district, NWT. has yielded 4 Kimberlite discoveries, the latest named Cedar, and it was found like the others; drilling a distinct EM anomaly.
This is the real secret of Arctic Star. They havet tremendous potential to revolutionize the way in which Diamonds are discovered – and become a pioneer in the exploration industry – by finding diamonds in a place where no previous explorer thought to do so. Now more than just a wild theory, Arctic Star has the team to back it up to continue the discovery process.
Here are the 3 things you need to know
1. World Class Diamond Finders
Arctic Star exploration has a highly experienced diamond exploration team previously responsible for numerous world class diamond mine discoveries. The team is led by Buddy Doyle who originally discovered Diavik Mine, Canada’s largest diamond mine in terms of carat production. Diavik’s exceptional grades make it one of the most valuable diamond mines in the world. Diavik is located in the Northwest Territories of Canada, where Arctic Star has 2 of their diamond properties.
Few geologists have seen 2 projects from discovery through to decision to mine. Mr. Doyle is recognized by his peers in the exploration industry as an authority on diamond exploration and kimberlite geology, and has authored/co-authored numerous papers on these subjects. He was awarded the 2007 Hugo Dummitt Award for excellence in Diamond exploration.
Roy Spencer – If that wasn’t enough, the geologist who discovered the multi-billion-dollar Grib Diamond Mine in Russia (see above). which is just 450 KMs away from Arctic Star’s project in Finland, has now joined Arctic’s Board of Directors! Clearly, the Arctic Star team has the credibility necessary to put forth a new thesis on how to find diamonds.
2. Brand New Exploration Model To Find Diamonds
In order to find diamonds, you need to first find Kimberlites. What are Kimberlites? Essentially, they are the rocks which contain diamonds. These kimberlite rocks are found underground in vertical structures known as kimberlite pipes. To illustrate in simple terms, see this basic image of a kimberlite pipe with kimberlite rocks inside of it. Arctic has to date, found 4 of these and plan on testing each kimberlite found for diamonds.
Kimberlite pipes are the biggest source of diamonds today. When exploration companies go looking for kimberlites, the industry standard for finding them is to look for magnetic signatures. This is done by taking a magnetic survey from the air and/or ground. with a device called a magnetometer. Now, most of you won’t understand what you are looking at – but here is an example of one of the company’s magnetic surveys on its Canadian Diagras property.
The most important thing to understand is that the industry looks for magnetic signatures ….. but Buddy Doyle and the accomplished Arctic Star team have developed a NON MAGNETIC THESIS. They believe they will find economic diamonds by locating Kimberlite that do not have a magnetic signature where previous explores sought not to look. Arctic in a sense is exploring for diamonds the opposite way the industry traditionally does. Arctic acquired property big mining company’s dropped, because they looked at them one way. Arctic is looking differently and success is occurring quickly for this small, yet accomplished exploration outfit. There are already multiple drill ready targets in 2 countries using this new way of looking for diamonds; and proven correct in one; Finland will be next to prove without a doubt Arctic HAS discovered a new way of finding diamonds.
Arctic offers multiple opportunities in 2 countries to turn the Diamond Industry on notice with a discovery.
3. Arctic Star Has Two Diamond Projects Ready To Verify Its Non-Magnetic Theory
Arctic has 2 diamond projects on which to verify its theory: Diagras in Northwest Territories of Canada and Timantti in Finland, where early exploration searching for Non-Magnetic signatures has already yielded multiple new diamond targets
A. Diagras is next to Diavik (Canada’s largest diamond mine) and has already proven Buddy’s Theory correct with 4 kimberlite discoveries to date, with plans to drill more.
B. Timantti in Finland has 3 separate target areas and 6 targets altogether identified through non-magnetic signatures as a means to find diamonds and further excel Buddy’s theory, it is the company’s goal to drill test in 2021
As Buddy Doyle and the Arctic Star team are proven correct, it will create a new discovery process for understanding how diamonds are brought to surface in areas previous explorers cared not to look. Arctic Star has the potential to create multiple discoveries and copycat companies trying to duplicate their success.
However, there is only one Buddy Doyle and Roy Spencer, which is why Arctic Star is the one Diamond Exploration Company every investor should be aware of.
Posted by AGORACOM
at 2:29 PM on Tuesday, May 18th, 2021
Biotech companies, by their very nature, can often be difficult to understand for investors… but in order to understand Cardiol, all you have to know is that the firm is developing therapies for heart disease and heart failure through cannabidiols.
Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).
The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™.
CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free. (less than 10 ppm)
Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.
The company gained a huge boost this month closing its “bought deal” short form prospectus offering for aggregate gross proceeds of approximately $22m. This came after upsizing from the previously announced $15m offering; and after receiving more than $10m earlier this year from the exercise of warrants and stock options.
So, the company now sits on an enviable war chest. And it has ambitious plans for the future.
David Elsley, Cardiol Therapeutics’ President & CEO, walks us through them…
